A variety of markers have been identified that can predict the efficacy of immunotherapy in breast cancer, such as programmed cell death-ligand 1 (PD-L1) expression level (9), tumor mutation burden (TMB) (10), microsatellite instability-high (MSI-H) (11), and defective mismatch repair (dMMR) (11). Here, CD274 is linked to breast carcinoma.